Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.» Read More
CNBC's Meg Tirrell has the details on a report from Express Scripts which shows prices on some prescription drugs are soaring.
Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.
The old-line tech firms, along with Apple, are minting bigger dividends for investors.
The Food and Drug Administration has approved the first so-called biosimilar drug for use in the United States. The New York Times reports.
Jason Kolbert, Maxim Group, provides perspective on big M&A deals in the biotech space.
Bristol-Myers hit a 14-year high after the company won expanded approval for its lung cancer drug more than 3-months ahead of schedule. Details, with CNBC's Meg Tirrell.
CNBC's Meg Tirrell has details on the biotech deal between AbbVie and Pharmacyclics.
Johnson & Johnson is nearing a deal to acquire U.S. cancer drugmaker Pharmacyclics.
The drugmaker's new policies prohibit the direct-to-prison sales of two of its drugs used in executions.
Constant vigilance is the method the Florida Keys has used to ward off mosquito-borne illnesses, but new methods may be on the horizon.
CNBC's Meg Tirrell reports on the new travel advisory for those heading to warmer climates regarding mosquito-borne diseases like dengue fever.
These 13 stocks have beat the growth of Berkshire Hathaway in the years since 1985. USA Today reports.
In the Nasdaq composite, financial, consumer services and health-care sectors have seen their weightings more than double.
CNBC's "Fast Money" traders discussed how to play the steadily rising sectors.
The tech-heavy index has continued to outperform both the S&P 500 and the Dow Jones Industrial Average, and has some worried.
The biotech sector is growing faster than anywhere in the market. Jason Kolbert, Maxim biotech analyst, says the market is loving the certainty in the sector.
Sarissa Capital will nominate two directors to Ariad Pharmaceuticals' board and seek the "imminent retirement" of Chief Executive Harvey Berger.
The drug that has saved millions from malaria is losing its efficacy in a much larger swath of territory than was previously known. The NYT reports.
Receptos CEO Faheem Hasnain told CNBC that "there's only one strategy to run a business."
Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.
Get the best of CNBC in your inbox